Samuel T. Wilkinson, MD

Yale Depression Research Program, Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut

JCP
CBT following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial
Original Research

May 4, 2026

In patients with major depression and suicidal ideation, adding a 16-week CBT course to esketamine led to greater improvements in suicidal ideation and depression severity than esketamine alone.
, , , et al
JCP
SSRI, SNRI, or Other Antidepressant Use Not Associated With Differential Outcomes in Ketamine or Esketamine Treatment
Brief Report

April 27, 2026

No group differences were seen between concurrent oral antidepressant class and clinical outcomes in patients treated with IV ketamine or IN esketamine.
, , , et al
JCP
Ketamine and Esketamine: Is There a Meaningful Clinical Difference?
Commentary

September 22, 2025

The authors comment on a recent chart review by Meisner and colleagues.
,
JCP
Comparing the Cognitive Effects of Repeated IV Ketamine and ECT in Patients with Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial
Original Research

September 3, 2025

Patients treated with ketamine demonstrated superior cognitive functioning compared with those treated with ECT following a 3-week treatment course. No differences between treatments were observed among responders in at...
, , , et al
JCP
Ketamine/Esketamine in Bipolar Depression in a Clinical Setting
Original Research

October 2, 2024

In a small sample of patients with bipolar depression treated with ketamine/esketamine, no evidence of mania or hypomania was seen during acute treatment.
, , , et al
JCP
Effects of ECT in Comorbid Depression and Dementia
Original Research

January 25, 2023

Limited data suggest a role for electroconvulsive therapy (ECT) in treating behavioral and psychological symptoms of dementia. Using a larger sample size than in previous reports, this study examined...
, , , et al
JCP
Ketamine in the Real World: Where Do We Go From Here?
Commentary

September 14, 2022

Dr Wilkinson comments on recent data and developments in the use of ketamine for mood disorders.
JCP
Original Research

September 14, 2021

Mental health care resource utilization and barriers to receiving mental health services among adults with major depression and suicidality are understudied. This study aimed to document the extensive burden...
, , , et al
JCP
Original Research

July 20, 2021

Only some patients with treatment-resistant depression who ultimately respond to esketamine plus an oral antidepressant do so within the first 2 doses. This study estimated the likelihood of ultimate...
, , , et al
JCP
Original Research

July 7, 2020

How many older adults receive electroconvulsive therapy (ECT) for treatment-resistant depression? Among those who receive ECT, how many finish the course? What factors might predict patients' continuation of ECT?...
, , , et al
JCP
Original Research

April 28, 2020

Read a study about esketamine nasal spray (oral antidepressant) and it's long-term safety, tolerability, and efficacy for treatment-resistant depression (TRD).
, , , et al
JCP
Original Research

July 24, 2018

Ketamine, an off-label treatment for depression, can have rapid-acting antidepressant effects but is also sometimes associated with negative clinical outcomes. Do the short- and long-term benefits of ketamine treatment...
, , , et al

Insightful. Evidence-based. Human-centered.

Listen to the JCP Podcast Now
Figure: Digital illustration shows a human head with neural connections and podcast title over a dark blue patterned background.

Subscribe to read
more articles

Subscribe